// App-Quantinova.ai

307 : Reductions in Abnormal Direct Bilirubin with Obeticholic Acid in Patients with Primary Biliary Cholangitis

Researchers

Presenter

  • Albert Pares

Principal Investigators

  • Victor Vargas

  • Mitchell L. Shiftman

  • Gideon M. Hirschfield

  • Pietro Invernizzi

  • Alexander Liberman

  • Elizabeth Smoot Malecha

  • Janet Owens-Grillo

  • Juan C. Lopez-Talavera

Medical Centers

  • BCLC Group, Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain

  • Liver Unit, Hospital Vall d'Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain

  • Liver Institute of Virginia, Newport News, VA

  • Centre for Liver Research, University of Birmingham, Birmingham, UK

  • Dept. of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy

  • Polaris Pharmaceuticals Inc, San Diego, CA

Locations

  • Spain

  • United States

  • United Kingdom

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Primary biliary cirrhosis

Biomarkers

  • Bilirubin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved